Pulsed delivery of inhaled nitric oxide to patients with primary pulmonary hypertension: An ambulatory delivery system and initial clinical tests

Chest

Volumn 109, Issue 6, 1996, Pages 1545-1549

  Channick, Richard N ^a   Newhart, John W ^a   Johnson, F Wayne ^a   Williams, Penny J ^a   Auger, William R ^a   Fedullo, Peter F ^a   Moser, Kenneth M ^a  

^a UCSD MEDICAL CENTER   (United States)

Author keywords

inhaled nitric oxide; nasal cannulas; outpatient administration; primary pulmonary hypertension; pulsed delivery

Indexed keywords

NITRIC OXIDE;

AMBULATORY CARE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG MECHANISM; HUMAN; HUMAN CELL; HUMAN TISSUE; LONG TERM CARE; LUNG VASCULAR RESISTANCE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; TREATMENT OUTCOME; VASODILATATION;

EID: 0029896789     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.109.6.1545     Document Type: Article

References (16)

1. Palmer RMJ, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 1988; 333:664-66
2. Ignarro LJ. Biological actions and properties of endothelium-derived nitric oxide formed and released from artery and vein. Circ Res 1989; 65:1-21
3. Pepke-Zaba J, Higenbottam TW, Dinh-Xuan AT, et al. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet 1991; 338:1173-74
4. Roberts JD, Lang P, Bigatello LM, et al. Inhaled nitric oxide in congenital heart disease. Circulation 1993; 87:447-53
5. Fratacci MD, Defouilloy C, Andrivet P, et al. Responses to infusion of acetylcholine and inhalation of nitric oxide in patients with chronic obstructive lung disease and pulmonary hypertension. Am Rev Respir Dis 1992; 145:A722
6. Channick RN, Hoch RP, Newhart JW, et al. Improvement in hypoxemia and pulmonary hypertension following nitric oxide inhalation in a patient with end-stage pulmonary fibrosis. Am J Respir Crit Care Med 1994; 149:811-14
7. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med 1987; 107:216-23
8. Channick RN, Newhart JW, Johnson FW, et al. Inhaled nitric oxide reverses hypoxic pulmonary vasoconstriction in dogs: a practical nitric oxide delivery and monitoring system. Chest 1994; 105:1842-47
9. Channick RN, Williams PJ, Newhart JW, et al. Inhaled nitric oxide results in more favorable hemodynamic and gas exchange responses than prostacyclin in patients with primary pulmonary hypertension. Am J Respir Crit Care Med 1994; 149:A746
10. Vesal N, Cremona G, Katayama Y, et al. Optimal inhalation of nitric oxide using the 'spiked' breath. Am J Respir Crit Care Med 1995; 151:A729
11. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327:76-81
12. Barst RJ, Rubin LJ, McGoon MD, et al. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 1994; 121:409-15
13. Azuma H, Ishikawa M, Sekizaki S. Endothelium-dependent inhibition of platelet aggregation. Br J Pharmacol 1986; 88:411-15
14. Radomski MW, Palmer RMJ, Moncada S. An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci USA 1990; 87:5193-97
15. Scott-Burden T, Vanhoutte PM. The endothelium as a regulator of vascular smooth muscle proliferation. Circulation 1993; 87(suppl V):V-51-5
16. Sitbon O, Brenot F, Denjean A, et al. Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. Am J Respir Crit Care Med 1995; 151:384-89